- Home
- SNAL vs RNTX Comparison
SNAL vs RNTX Comparison
Compare SNAL & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNAL | RNTX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 38.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNAL | RNTX |
|---|---|---|
| Price | $0.97 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 26.1K | ★ 184.8K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,330,445.00 | N/A |
| Revenue This Year | $13.87 | N/A |
| Revenue Next Year | $26.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $1.04 |
| 52 Week High | $3.42 | $3.50 |
Technical Indicators
Market Signals| Indicator | SNAL | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 58.01 |
| Support Level | $0.87 | $1.34 |
| Resistance Level | $1.00 | $1.58 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 41.24 | 87.50 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.